Journal of Managed Care & Specialty Pharmacy

Article	Citations
Correction	109
What is needed to sustain comprehensive medication management? One health plan’s perspectives	58
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	45
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review	23
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	20
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	20
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	20
The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: Real-world evidence from US	18
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues	18
PIVOT: Pharmacist Interventions for Value and Outcome Transformation in Specialty Pharmacy	17
Compliance with the Veterans Health Administration’s Pharmacy Benefit Management guidance for duration of clopidogrel following peripheral vascular interventions: a retrospective cohort study	15
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	15
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	14
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy	14
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	13
Principles and practices for successful gene therapy innovative contracting: insights from a multistakeholder convening	13
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey	12
Real-world evidence: A new era is upon us	12
Poster Abstracts - Academy of Managed Care Pharmacy 2024	11
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	11
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria	11
Patient factors and costs associated with prophylactic neurokinin-1 receptor antagonist use among women with invasive breast cancer	11
Real-world primary nonadherence to antiobesity medications	11
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	11
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	10

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	10
Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study	10
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	10
AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitis	10
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	10
Introducing the Managed Care Pharmacy Primer Series	9
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	9
Impact of a pharmacist-led hepatitis C clinic on hepatitis A and B vaccination rates and treatment outcomes: A retrospective cohort study	9
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer	9
Poster Abstracts - Academy of Managed Care Pharmacy 2026	9
Impact of telehealth on hydroxyurea adherence and clinical outcomes in sickle cell disease management: A systematic review and meta-analysis	8
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population	8
Trends in delivery of comprehensive medication reviews by race and ethnicity, 2013-2021	8
From access to equity: The devil is in “Z” details	8
First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eli	8
Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States	8
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	8
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	8
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	8
Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs	8
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States	8
Addressing gaps to strengthen patient-centricity in formulary decision-making: An example applied to Colorado’s prescription drug affordability board implementation	8
Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States	8
AMCP Format for Formulary Submissions 5.0	8
Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin	8
Evolution of the Military Health System compounded drugs utilization and management	8
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer	8
Correction	8
The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United	8
Trends in opioid prescribing by oncologists for Medicare beneficiaries from 2014 to 2022	8
Place of care and costs associated with acute episodes and remission in schizophrenia	8
Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: A claims-based analysis	7
Cost sharing in managed care and the ethical question of business purpose	7
Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act’s Medicare Drug Price Negotiation Program	7
Resmetirom for nonalcoholic steatohepatitis	7
Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid	7
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	7
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	7
Poster Abstracts - Academy of Managed Care Pharmacy 2025	7
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States	7
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States	7
Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act	7
A dynamic analysis of medication adherence	7
When are breakthrough therapies cost-effective?	7
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	6
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder	6
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria	6
Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis	6
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	6
Infusion therapy patient outcomes are similar at reduced costs in alternative sites of care compared with hospital outpatient departments: A matched cohort analysis of infusion therapy across multiple	6

Trends in use of continuous glucose monitors among individuals with type 2 diabetes enrolled in Medicare Advantage (2021–2023)	6
Use of clinical outcome assessments in specialty drug coverage policies	6
Correction	6
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma	6
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States	6
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value	6
Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement	6
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program	6
AMCP Market Insights: Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care	6
Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis	6
AMCP Market Insights: Payer best practices in food allergy management	6
Treatment patterns, health care resource utilization, and costs of heavily treatment-experienced people with HIV in the United States	6
The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review	6
Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste	6
Characterizing Medicare Medication Therapy Management program enrollees with central nervous system–active polypharmacy	6
Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis	6
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	5
Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy	5
Health care costs and resource utilization among patients with myasthenia gravis in the United States	5
Building health plan–pharmacist provider partnerships to optimize medication outcomes	5
Correction Statement	5
Will the emerging private-label market access channel help or hinder biosimilar market access?	5
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	5
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	5
Limited utility of price transparency data for drugs	5
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	5
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis	5
Health care resource utilization and costs among patients with spasticity or cervical dystonia	5
Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives	5
Oral treatments for outpatient COVID-19: Effectiveness and value	5
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	5
Socioeconomic, demographic, and medication class determinants of medication adherence: A retrospective cohort study	5
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	5
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	5
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review	5
Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States	5
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah	5
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	5
Herpes zoster vaccine uptake following provider prescription among older adults in the United States	5
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	5
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	5
Advancing the conversation: 30 years of scholarship in managed care pharmacy	5
Effect of the initial combination approach vs initial monotherapy approach on 1-year trajectories of adherence in drug-naive patients with type 2 diabetes	4
Impact of copay maximizers on total patient liability among patients using specialty medicines	4
Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States	4
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	4
Pathways for innovation—Expansion of health system specialty pharmacy services: A pilot initiative in dermatology and rheumatology clinics	4
Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease	4
Pharmacist vs physician management of e-visit requests for COVID-19 medication: A randomized clinical trial	4
Prevalence, adherence, and health care resource utilization in schizophrenia: A national and state-level analysis of US Medicaid Beneficiaries	4
Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: Toward a strategy for improving risk and managing costs	4
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema	4
Impact of a pharmacy care management service on cardiometabolic medication adherence and resource use for Medicare Advantage beneficiaries	4
The effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa	4
Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma	4
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States	4
Primary care physicians prescribe fewer expensive combination medications than dermatologists for acne: A retrospective review	4
Poster Abstracts - Academy of Managed Care Pharmacy 2022	4
The effectiveness and value of suzetrigine for moderate to severe acute pain: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council	4
Marginal health care expenditures for melanoma care in the United States	4
Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis	4
Atidarsagene autotemcel for metachromatic leukodystrophy	4
Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	4
HIV preexposure prophylaxis treatment patterns in a national health plan population	4
Correction	4
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	4
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective	4
Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States	4
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cance	4
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension	4
Finding consensus on meaningful reporting measures for rheumatoid arthritis: Results from a modified Delphi study	4
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	4
Improving adherence to guideline-based lipid-lowering therapy in people with hyperlipidemia using a targeted educational outreach approach	4
A primer on copay accumulators, copay maximizers, and alternative funding programs	4
Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste	4
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	4
Characterizing health plan evidence review practices	4
Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States	4
Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States	4
Predicting pharmacy choice for managed care network design	4

Emerging trends in pharmacy operations: Perspectives on the 2024 AMCP Foundation Survey	4
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	4
Health care utilization and costs associated with acute exacerbation of fibrosing interstitial lung disease in the United States: A retrospective administrative claims database analysis	4
AMCP Market Insights: Payer best practices for timely diagnosis and optimal management of idiopathic hypersomnia	4
Marginal health care expenditures and health-related quality of life burden in patients with migraine	4
Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care	4
Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi	4
Thanks to JMCP Peer Reviewers, 2025	4
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	4
Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes	4
Pharmacoequity measurement framework: A tool to reduce health disparities	4